Key Takeaways
- Sharp inventory hit in a weak quarter: Revenue fell 8% YoY to ₹204 crores, but the real damage was a ₹17 crores inventory write-down that compressed margins, with management calling the bottom on further losses.
- Export demand collapsed, domestic held: Export revenue dropped 17% YoY to ₹84 crores on destocking and adverse weather, while domestic stayed flat at ₹117 crores, though domestic margins bore the brunt of the price pressure.
- Product mix is masking price erosion: Volumes fell 8-10% YoY, but blended price per kg held flat because new, higher-priced products grew their share, a shift that also mechanically compresses percentage margins.
- Management is calling a stabilization, not a recovery: Raw material prices are seen bottoming out and destocking should end in 3-4 months, but the company refused to call when selling prices will recover, calling it "very difficult to tell."
- What to watch next quarter: Whether the promised ₹20 crores inventory reduction materializes, any sign of export volume recovery as destocking ends, and if the 18-20% EBITDA margin band holds through Q2.
The Inventory Shock
- ₹17 crores hit, two parts: ₹9 crores from an NRV write-down on high-cost inventory and ₹7.3 crores from selling ₹20 crores worth of product below cost after prices fell 30-40% in some products.
- Domestic import-substitute products took the damage: The NRV hit landed on import-substitute products launched last year under Aatma Nirbhar Bharat, where the company had no pass-on agreements with local suppliers and had stocked up for the March-July season.
- Export margins were protected: Major export agreements allow adjustment with raw material prices, so export margins stayed more or less intact; only marginal effects possible on smaller supplies.
- Raw material cost trap: When importing from China, prices were high initially and then continuously declined, leaving the company always holding higher-cost inventory, a dynamic management called "the trouble."
- No further large losses expected: Management has provided for inventory per NRV and sees maybe 1-2% more at most, unless there is a significant price revision in August-September, which is not foreseen.
S. P. Gupta: "See we are not hoping for any significant losses since we have provided for inventory, as per NRV. Maybe 1% or 2% may be there, but most of the losses, they have been provided for in this June quarter."
Price & Margin Mechanics
- Volume down, blended price flat: Sales decline was mainly through volumes (8-10% de-growth YoY), while blended average price per kg remained similar because new products with higher selling prices increased their contribution.
- The margin compression paradox: New higher-priced products carry roughly ₹150 per kg gross margin regardless of product price, so as the mix shifts from a ₹400/kg product to a ₹600/kg product, percentage margins compress even though absolute margin per kg is unchanged.
- Price decline was broad-based: Almost all products fell, and management stressed this is not unique to the company: all agrochemical and chemical manufacturing companies are feeling the same thing.
- EBITDA margin target held at ~20%: Management expects to maintain EBITDA margins around 20% and will try to improve through proper molecule selection, with a band of 18-20% for FY24 given market volatility.
- Q2 should improve: This quarter was slightly subdued, but from next quarter onwards margins are expected to improve as inventory losses fade and capacity utilization picks up.
D.K. Jain: "So, we expect to maintain the EBITDA margins of around 20%, and we will try our best to improve this further on by proper selection of the molecules. We are in always search of molecules for this niche areas."
Demand & Destocking
- Export demand collapsed on two fronts: Adverse weather conditions in international markets and inventory destocking, particularly in Europe, drove export revenue down from ₹101 crores to ₹84 crores YoY.
- Domestic held steady but at a cost: Domestic revenue was flat at ₹117 crores, but margin pressure was majority for domestic sales because local import-substitute products lack the pass-on agreements that protect export margins.
- Customers are in wait-and-watch mode: Buyers quote lower prices each time and are deferring purchases rather than buying in bulk, a dynamic management described as pervasive across the industry.
- Destocking seen ending in 3-4 months: Management expects the destocking cycle to be over by another three to four months, though they declined to call when selling prices would actually recover.
- Capacity utilization dropped to ~50%: Lowered utilization reflects both increased capacity and lesser demand from international markets; July is already showing improvement in both utilization and rates.
D. K. Jain: "The prices are still slightly falling sir, because when we talk about what is happening, then the customers, whenever they quote a price, they would like to quote a lower price. That is how things are going on and everybody is in wait and watch mode somehow because they don't want to make all their purchases at the same time."
New Products & Pipeline
- New products are the growth engine: Recently launched products continue to receive positive market response and are making significant contribution to the top line, with ₹170-175 crores expected from new products in FY24.
- Four technical launches planned this year: Three technical products (two import substitutes, one for export) and one intermediate, plus more than 10 combination formulations in B2C sales.
- Hamirpur plant progressing: Work is ongoing with the first product launch targeted for Q4 FY24; capex completing by March 2024 should contribute partially in FY25 with full impact the year after.
- Pharma intermediates entry: R&D team expanded with two senior scientists specialized in pharma intermediates, stabilizers, and additives; commercialization expected in FY25, first or maximum second quarter.
- US registration milestone: Company has placed orders for supply and expects to start supplying from next month onwards, with roughly ₹20 crores ordered for this year.
- Stabilizers and additives in the pipeline: Working on stabilizers for common use and chemical stabilizers and additives, tracking a few molecules with IICT Hyderabad under Shalvis Specialities, with products probably next year.
Capex & Balance Sheet
- ₹50 crores capex for IPL in FY24: Roughly 50% for two new blocks (one intermediate, one technical), with the remainder for infrastructure augmentation including a 33 KVA power supply line to replace 11 KVA and reduce overall power cost.
- Shalvis Specialities adding ₹60 crores: Total group capex of ₹110 crores planned, funded through internal accruals.
- Working capital improved: Working capital days reduced by 20 days from March 2023 levels, driven by lower inventory; debtor days remained the same and no abnormal sales returns were experienced.
- Inventory reduction target: Expecting inventory to further reduce by ₹20 crores by end of Q2.
- Technical capacity expanded: Added another 200 metric tons during the quarter, taking total technical capacity to 24,200 metric tons.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Inventory reduction | Reduce inventory by ₹20 crores from current levels | By end of Q2 FY24 |
| No further significant inventory losses | Only 1-2% possible unless unforeseen price revision in Aug-Sep | Q2 FY24 |
| New products contribution | ₹170-175 crores revenue from new products | FY24 |
| Top line growth | ~10% growth if situation normalizes | FY24 (second-half dependent) |
| EBITDA margin | Maintain ~20%, band of 18-20% | FY24 |
| Destocking ends | Destocking cycle over | 3-4 months |
| Hamirpur first product launch | First product from new plant | Q4 FY24 |
| US supply begins | Start supplying to US market, ~₹20 crores ordered | From next month onwards |
| Pharma intermediates commercialization | Commercial launch | FY25 (Q1 or max Q2) |
| FY25 revenue growth | At least 15% (previously 20-25%, rationalized for lower product prices) | FY25 |
| Long-term consolidated growth | More than 20% | Long-term basis |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue | ₹204.7 cr, compared to ₹221.7 cr in Q1 FY23 |
| EBITDA | ₹26 cr |
| EBITDA margin (adjusted for inventory loss) | ~21%, compared to historical 27–28% |
| PAT | ₹16 cr, compared to ₹41 cr in Q1 FY23 |
| Inventory loss impact (destocking/NRV) | ₹17 cr, comprising ₹7.3 cr on sales and ₹9.8 cr on inventory revaluation |
| Revenue from exports | ₹84 cr, compared to ₹101 cr in Q1 FY23; 42% of overall sales |
| Domestic revenue | ₹117 cr, similar to Q1 FY23 |
| Technical revenue | ₹158 cr |
| Formulations revenue | ₹43 cr |
| Volume de-growth (YoY) | 8–10% |
| FY24 revenue growth guidance | ~10%, if situation normalizes in H2 |
| FY25 revenue growth guidance | at least 15% |
| Long-term consolidated growth target | more than 20% |
| Contribution from new products | ₹40 cr in Q1; FY24 expectation ₹170–175 cr |
| Capacity utilization | slightly more than 50% |
| Capex incurred in Q1 (Sandila expansion) | ₹16 cr |
| FY24 capex plan (IPL) | ₹50 cr |
| FY24 capex plan (Shalvis Specialities) | ₹60 cr |
| Cash and cash equivalents | ₹136 cr at end of Q1 |
| Inventory | ₹190 cr at end of June, down from ₹225 cr in March; expected to reduce by ₹20 cr by end of Q2 |
| Working capital days | reduced by 20 days from March 2023 levels |
| Asset turnover expectation (Sandila and Hamirpur) | 2.25x to 2.5x |
| US client order for FY24 | ~₹20 cr |
| Raw material sourcing from China | ~17% of total raw materials (per an analyst's math) |